These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 9696850)

  • 41. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors.
    Doyon L; Payant C; Brakier-Gingras L; Lamarre D
    J Virol; 1998 Jul; 72(7):6146-50. PubMed ID: 9621079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
    Tojo Y; Koh Y; Amano M; Aoki M; Das D; Kulkarni S; Anderson DD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3460-70. PubMed ID: 20439612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational studies of the resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new derivatives.
    Nair AC; Bonin I; Tossi A; Wels WJ; Miertus S
    J Mol Graph Model; 2002 Dec; 21(3):171-9. PubMed ID: 12463635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors.
    Watkins T; Resch W; Irlbeck D; Swanstrom R
    Antimicrob Agents Chemother; 2003 Feb; 47(2):759-69. PubMed ID: 12543689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
    Masse S; Lu X; Dekhtyar T; Lu L; Koev G; Gao F; Mo H; Kempf D; Bernstein B; Hanna GJ; Molla A
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3075-80. PubMed ID: 17576848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 protease-substrate coevolution in nelfinavir resistance.
    Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
    J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB
    J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374.
    Stray KM; Callebaut C; Glass B; Tsai L; Xu L; Müller B; Kräusslich HG; Cihlar T
    J Virol; 2013 Jan; 87(1):454-63. PubMed ID: 23097440
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.
    Martins AN; Waheed AA; Ablan SD; Huang W; Newton A; Petropoulos CJ; Brindeiro RD; Freed EO
    J Virol; 2016 Jan; 90(2):768-79. PubMed ID: 26512081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.
    Dauber DS; Ziermann R; Parkin N; Maly DJ; Mahrus S; Harris JL; Ellman JA; Petropoulos C; Craik CS
    J Virol; 2002 Feb; 76(3):1359-68. PubMed ID: 11773410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.
    Kolli M; Lastere S; Schiffer CA
    Virology; 2006 Apr; 347(2):405-9. PubMed ID: 16430939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.
    van Maarseveen NM; Andersson D; Lepšík M; Fun A; Schipper PJ; de Jong D; Boucher CA; Nijhuis M
    Retrovirology; 2012 Apr; 9():29. PubMed ID: 22462820
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
    Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
    Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
    Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.
    Raugi DN; Smith RA; Ba S; Toure M; Traore F; Sall F; Pan C; Blankenship L; Montano A; Olson J; Dia Badiane NM; Mullins JI; Kiviat NB; Hawes SE; Sow PS; Gottlieb GS;
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2751-60. PubMed ID: 23571535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.